Agenus advances Phase 3 ROBBIN trial of botensilimab-balstilimab in neoadjuvant MSS colon cancer
AGEN•AGEN•AGEN•AGEN•An oversubscribed private placement raised USD 85 million upfront, with milestone-linked warrants for up to USD 255 million to fund execution.
Management framed the target setting as a large, underserved market, estimating more than USD 7 billion in annual U.S. sales potential.
Agenus advanced plans for ROBBIN, a global Phase 3 neoadjuvant trial of botensilimab with balstilimab in high-risk Stage II-III MSS colon cancer; first dosing is expected in Q1 2027.
The trial launch follows results already presented from NEST and UNICORN, showing strong tumor clearance before surgery with no recurrences reported at the cutoffs.
